Cancer “Moonshot” Launch Team Announced: Uncomfortable Ties To Anti-Industry Headlines
This article was originally published in RPM Report
The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.
Register for our free email digests: